Nuvilex, Inc. (OTC: NVLX) is a biotechnology company with rights to use a proprietary cellulose-based live-cell encapsulation technology, known as Cell-in-a-Box, for the development of treatments for cancers and for diabetes worldwide. The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer that combines the Cell-in-a-Box technology with the anti-cancer drug ifosfamide. This treatment has completed Phase 1/2 clinical trials. For more information, visit the company’s website at www.nuvilex.com.